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AAP. *See* American Academy of Pediatrics (AAP)

Acyclovir

 dosing in infants, 185--187

American Academy of Pediatrics (AAP)

 COFN of, 199--204

Amphotericin B deoxycholate

 dosing in infants, 179--182

Amphotericin B lipid complex

 dosing in infants, 179--182

Ampicillin

 dosing in infants, 168--169

Anidulafungin

 dosing in infants, 184--185

Antibiotic(s)

 in bacterial meningitis in infants management, 37

 broad-spectrum

 in premature infants, 108

 for CA, 160--161

 dosing of. *See* Antibiotic dosing

 novel

 for staphylococcal infections in infants, 126

 risks associated with, 196

Antibiotic dosing

 in infants, **167--176**

 ampicillin, 168--169

 clindamycin, 169--171

 introduction, 167--168

 meropenem, 171

 metronidazole, 172

 piperacillin/tazobactam, 172--174

Antibiotic stewardship, **195--206**

 AAP COFN on, 199--204

 CDC on, 196--199

Antifungal dosing

 in infants, **177--185**

 echinocandins, 184--185

 introduction, 177--179

 polenes, 179--182

 triazoles, 182

Antimicrobial agents. *See* Antibiotic(s)

Antistaphylococcal penicillin

 in infants, 124

Antiviral dosing

 in infants, **185--189**

 acyclovir, 185--187

 ganciclovir, 187--188

 introduction, 177--179

 valacyclovir, 185--187

 valganciclovir, 187--188

Astrovirus

 NEC due to, 141
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Bacteremia

 UTIs in infants and, 21

Bacteria

 NEC due to, 134--138

 atypical bacteria, 138

 gram-negative bacteria, 137--138

 gram-positive bacteria, 135--137

Bacterial meningitis

 described, 30

 in infants, **29--45**

 causes of, 31

 clinical presentation of, 33

 in developed countries, 30--31

 in developing countries, 31

 diagnosis of, 33--36

 ancillary tests in, 35

 CSF parameter interpretation in, 35

 lumbar puncture in, 33--37

 epidemiology of, 30--31

 introduction, 30

 long-term outcomes of, 38

 pathogenesis of, 32--33

 prevention of, 38--40

 risk factors for, 33

 treatment of, 37--38

Birth weight

 candidiasis related to, 107

Bloodstream infections (BSIs), **1--16**

 causative agents, 6--8

* Candida* spp., 8

 CoNS, 6--7

* Enterococcus* spp., 7

 gram-negative organisms, 7

* S. aureus,* 7

 control and prevention of, 10

 definitions of, 2

 described, 1

 epidemiology of, 2

 incidence of, 2

 introduction, 1

 resistance to, 8--10

 risk factors for, 3--6

 central lines, 3--5

 medications, 5

 NICU environment, 5--6

BPD. *See* Bronchopulmonary dysplasia (BPD)

Brain disease

 CA and, 159

Broad-spectrum antibiotics

 candidiasis related to, 108

Bronchopulmonary dysplasia (BPD)

 CA and, 160

BSIs. *See* Bloodstream infections (BSIs)
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CA. *See* Chorioamnionitis (CA)

*Candida* spp.

 BSIs due to, 8

 NEC due to, 141

Candidiasis

 in premature infants, **105--117**

 background of, 105--106

 diagnosis of, 109--111

 microbiology of, 109

 pathogenesis of, 106

 risk factors for, 106--109

 broad-spectrum antibiotics, 108

 central venous catheters, 108

 NICU environment, 107--108

 prematurity and birth weight, 107

 treatment of, 111--112

Candiduria

 treatment of, 22

Caspofungin

 dosing in infants, 184--185

CDC. *See* Centers for Disease Control and Prevention (CDC)

Centers for Disease Control and Prevention (CDC)

 in antibiotic stewardship, 196--199

Central line(s)

 BSIs related to, 3--5

Central line--associated blood stream infections (CLABSIs), 3--5

 epidemiology of, 2

 incidence of, 2

Central nervous system (CNS)

 bacterial meningitis of

 in infants, 33

Central venous catheters

 candidiasis related to, 108

Cerebrospinal fluid (CSF) parameters

 interpretation of

 in bacterial meningitis in infants diagnosis, 35

Children

 drugs in

 mechanisms for study of, 168

Chorioamnionitis (CA), **155--165**

 defined, 155--157

 management of, 160--161

 in neonates, **155--165**

 outcomes of, 158--160

 BPD, 160

 brain disease, 159

 lung disease, 159

 neonatal sepsis, 158

 preterm birth, 158

 respiratory distress syndrome, 159--160

 pathophysiology of, 157--158

CLABSIs. *See* Central line--associated blood stream infections (CLABSIs)

Clindamycin

 dosing in infants, 169--171

 for staphylococcal infections in infants, 125

*Clostridia* spp.

 NEC due to, 136--137

CMV\. *See* Cytomegalovirus (CMV)

CNS. *See* Central nervous system (CNS)

Coagulase-negative *Staphylococcus* (CoNS)

 BSIs related to, 6--7

 clinical manifestations of, 123

 diagnosis of, 123

 epidemiology of, 121--122

COFN. *See* Committee on the Fetus and Newborn (COFN)

Committee on the Fetus and Newborn (COFN)

 of AAP, 199--204

CoNS. *See* Coagulase-negative *Staphylococcus* (CoNS)

Coronavirus

 NEC due to, 140

*Cronobacter sakazakii*

 NEC due to, 137--138

CSF. *See* Cerebrospinal fluid (CSF)

Cytomegalovirus (CMV)

 NEC due to, 139--140

 perinatal, **61--75**

 clinical correlation, 64--70

 diagnostics in, 67--70

 discussion, 71--72

 introduction, 61--62

 prevalence/incidence of, 63--64

 prevention/treatment of

 infant interventions for, 66--67

 maternal interventions for, 64--66

 vaccines for

 maternal

 research related to, 70--71
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Drug(s)

 BSIs due to, 5

 in children

 mechanisms for study of, 168

E

Early onset sepsis (EOS)

 described, 195--196

Echinocandins

 dosing in infants, 184--185

Empirical therapy

 for staphylococcal infections in infants, 126

*Enterococcus* spp.

 BSIs related to, 7

Enterocolitis

 necrotizing. *See* Necrotizing enterocolitis (NEC)

Enteroviruses

 NEC due to, 140--141

EOS. *See* Early onset sepsis (EOS)

*Escherichia coli*

 NEC due to, 138

 UTIs in infants due to, 18
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Fluconazole

 dosing in infants, 182--183

Fungus(i)

 NEC due to, 141
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Ganciclovir

 dosing in infants, 187--188

GBS. *See* Group B streptococcus (GBS)

Gram-negative organisms

 BSIs related to, 7

Group B streptococcus (GBS) vaccine

 in bacterial meningitis in infants prevention, 38--40
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Hepatitis

 B, 92--94

 clinical correlation, 93

 described, 92

 diagnosis and treatment of, 93--94

 discussion, 93--94

 epidemiology of, 93

 transmission/pathogenesis of, 92--93

 C, 94--95

Herpes simplex virus (HSV)

 described, 48

Herpes simplex virus (HSV) infection

 maternal

 clinical features of, 49--50

 terminology related to, 49

 mother-to-child transmission of

 prevention of, 52--53

 risk factors for, 50--51

 neonatal, **47--59**

 clinical features of, 51--52

 described, 48

 epidemiology of, 48--49

 introduction, 47--48

 treatment of, 53--56

HIV

 NEC due to, 141

HIV infection

 perinatal, 88--92

 described, 88

 diagnosis and treatment of, 89--92

 discussion, 89--92

 epidemiology of, 88--89

 transmission/pathogenesis of, 89

HSV. *See* Herpes simplex virus (HSV)
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Infant(s)

 antibiotic dosing in, **167--176**. *See also* Antibiotic dosing, in infants

 antifungal dosing in, **177--185**. *See also* Antifungal dosing, in infants

 antiviral dosing in, **185--189**. *See also* Antiviral dosing, in infants

 bacterial meningitis in, **29--45**. *See also* Bacterial meningitis, in infants

 premature

 candidiasis in, **105--117**. *See also* Candidiasis, in premature infants

 staphylococcal infections in, **119--132**. *See also* Staphylococcal infections, in infants

 uncircumcized

 UTIs in, 19

 UTIs in, **17--28**. *See also* Urinary tract infections (UTIs), in infants

Infection(s). *See also specific types*

 bloodstream, **1--16**

 staphylococcal

 in infants, **119--132**

 TORCH, **77--103**
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*Klebsiella* spp.

 NEC due to, 138
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Linezolid

 for staphylococcal infections in infants, 125--126

Liposomal amphotericin

 dosing in infants, 179--182

Lumbar puncture

 in bacterial meningitis in infants diagnosis, 33--37

Lung disease

 CA and, 159
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Medication(s). *See* Drug(s)

Meningitis

 bacterial

 in infants, **29--45**. *See also* Bacterial meningitis

 neonatal

 prevention of, 38--40

 UTIs in infants and, 21

Meropenem

 dosing in infants, 171

Methicillin resistance

 in staphylococcal infections in infants, 123--124

Metronidazole

 dosing in infants, 172

Micafungin

 dosing in infants, 184--185
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NEC. *See* Necrotizing enterocolitis (NEC)

Necrotizing enterocolitis (NEC)

 infectious causes of, **133--154**. *See also specific causes, e.g.,* Bacteria

 bacteria, 134--138

 fungi, 141

 introduction, 133--134

 viruses, 138--141

Neonatal intensive care unit (NICU)

 BSIs due to, 5--6

 candidiasis in, 107--108

Neonatal sepsis

 CA and, 158

Neonate(s)

 CA in, **155--165**. *See also* Chorioamnionitis (CA)

 HSV infection in, **47--59**. *See also* Herpes simplex virus (HSV) infection, neonatal

NICU. *See* Neonatal intensive care unit (NICU)

Norovirus

 NEC due to, 139

P {#sec13}
=

Parvovirus B19, 86--88

 clinical correlation, 87

 described, 86

 diagnosis and treatment of, 87--88

 discussion, 87--88

 transmission/pathogenesis of, 86--87

Penicillin

 for staphylococcal infections in infants, 124

Piperacillin/tazobactam

 dosing in infants, 172--174

Polene(s)

 dosing in infants, 179--182

Premature infants

 candidiasis in, **105--117**. *See also* Candidiasis, in premature infants

Preterm birth

 CA and, 158

*Pseudomonas* spp.

 NEC due to, 138

Pyuria

 defined, 21--22
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Renal abnormalities

 UTIs in infants due to, 19

Respiratory distress syndrome

 CA and, 159--160

Rotavirus

 NEC due to, 138--139

Rubella, 85--86
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Sepsis

 early onset, 195--196

Staphylococcal infections

 in infants, **119--132**

 clinical manifestations of, 123

 diagnosis of, 123

 epidemiology of, 120--122

 introduction, 119--120

 resistance to, 123--124

 treatment of, 124--126

*Staphylococcus* spp.

 coagulase-negative. *See* Coagulase-negative *Staphylococcus* (CoNS)

* S. aureus*

 BSIs due to, 7

 clinical manifestations of, 123

 diagnosis of, 123

 epidemiology of, 120--121

* S. epidermidis*

 NEC due to, 135--136

Steroid(s)

 antenatal

 for CA, 161
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TORCH infections, **77--103**. *See also specific infections, e.g.,* Toxoplasmosis

 HBV, 92--94

 HCV, 94--95

 introduction, 77--78

 parvovirus B19, 86--88

 perinatal HIV infection, 88--92

 rubella, 85--86

 toxoplasmosis, 78--82

* Treponema pallidum,* 82--85

Toxoplasmosis, 78--82

 clinical correlation, 81--82

 described, 78

 diagnosis and treatment of, 82

 discussion, 82

 epidemiology of, 80--81

 transmission/pathogenesis of, 78--80

*Treponema pallidum,* 82--85

 clinical correlation, 83--84

 described, 82--83

 diagnosis and treatment of, 84--85

 discussion, 84--85

 epidemiology of, 83

 transmission/pathogenesis of, 83

Triazole(s)

 dosing in infants, 182--184
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Uncircumcized infants

 UTIs in, 19

Urinary tract infections (UTIs)

 in infants, **17--28**

 causes of

  *E. coli,* 18

 maternal history of UTIs, 19--20

 renal abnormalities, 19

 uncircumcized males, 18--19

 clinical correlations, 20--21

 concomitant bacteremia and meningitis, 21

 diagnosis of, 21--22

 epidemiology of, 17--20

 in first three days of life, 17

 introduction, 17

 recurrence of, 23

 risk factors for, 17--20

 treatment of, 22--23

 maternal history of

 UTIs in infants related to, 19--20

UTIs. *See* Urinary tract infections (UTIs)
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Vaccine(s)

 CMV

 maternal

 research related to, 70--71

 GBS

 in bacterial meningitis in infants prevention, 38--40

Valacyclovir

 dosing in infants, 185--187

Valganciclovir

 dosing in infants, 187--188

Vancomycin

 for staphylococcal infections in infants, 124--125

Vancomycin resistance

 in staphylococcal infections in infants, 124

Varicella zoster virus (VZV) infection

 perinatal, **61--75**

 discussion, 71--72

 introduction, 63

 prevalence/incidence of, 63--64

 prevention/treatment of

 infant interventions for, 66--67

 maternal interventions for, 64--66

Virus(es)

 NEC due to, 138--141

 astrovirus, 141

 CMV, 139--140

 coronavirus, 140

 enteroviruses, 140--141

 HIV, 141

 norovirus, 139

 rotavirus, 138--139

Voriconazole

 dosing in infants, 183--184

VZV infection. *See* Varicella zoster virus (VZV) infection
